Vincent Ma, MD

Follow Dr. Ma:

Education

• University of Nevada School of Medicine, Reno, Nevada – MD
• University of Michigan Health System, Ann Arbor, Michigan – Internal Medicine Residency
• University of Michigan Rogel Cancer Center, Ann Arbor, Michigan – Hematology and Oncology Fellowship

Professional Activities

Dr. Vincent Ma is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine and a faculty affiliate of the Department of Dermatology. He currently serves as co-chair of the Big Ten Cancer Research Consortium Melanoma/Cutaneous Oncology Clinical Trial Working Group and is the Immuno-Oncology Therapeutics Lead in the Early Phase Oncology Therapeutics Program and the Faculty Lead for Non-Melanoma Advanced Cutaneous Malignancies at the University of Wisconsin Carbone Cancer Center.

Dr. Ma is a member of the American Society of Clinical Oncology (ASCO), the Society for Immunotherapy of Cancer (SITC), American Association for Cancer Research (AACR), the Society of Melanoma Research, SWOG, and the ECOG-ACRIN Cancer Research Group. He is a recipient of the ASCO Conquer Cancer Merit Award (2021, 2024), the 40 Under 40 in Cancer Award (2022), and is a KL2 Scholar. He is also a member of the American Board of Internal Medicine (ABIM) Item-Writing Task Force for Medical Oncology - Melanoma/Skin Cancer questions. 

Clinical Specialties

Dr. Ma’s primary clinical interests are the diagnosis, treatment, and surveillance of melanoma and other advanced stage cutaneous malignancies, including Merkel cell carcinoma, cutaneous squamous cell carcinoma, and basal cell carcinoma. Dr. Ma developed the service line to establish the University of Wisconsin as an authorized treatment center for tumor-infiltrating lymphocyte (TIL) therapy. He also led the implementation of melphalan percutaneous hepatic perfusion therapy (Hepzato) at UW Health to treat patients with metastatic uveal melanoma with liver involvement. 

Dr. Ma also has interest in the management of immune-related adverse events from immune checkpoint inhibitor (ICI) therapy and is one of the co-founders of the ICI Toxicity Initiative working group at the University of Wisconsin.

Research Interests

View Dr. Vincent Ma's publications on NCBI MyBibliography

Dr. Ma’s research focus is on optimizing therapeutic strategies in melanoma and other advanced cutaneous malignancies with an emphasis in early phase clinical trial investigation involving immunotherapy and molecular targeted agents. He has clinical trial experience, serving as principal and sub-investigator on multiple cooperative group and industry sponsored studies. He is an active member of the UW Carbone Cancer Early Phase Oncology Therapeutics Program and Melanoma Disease Oriented Team group.